Despite its significant overall efficacy, BCG fails to benefit a substantial proportion of bladder cancer (BlCa) patients. Here, we review recent data highlighting the role of tumor microenvironment (TME) in limiting antitumoral activity of BCG treatment and emerging opportunities to target TME to enhance the overall outcomes in BCG-treated BlCa patients.
No takes yet. Share an insight, caveat, or question.
Ibrahim et al. (2020) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: